RESUMO
2'-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent. For the assessment of the extent to which systemically administered DCF crosses into the central nervous system (CNS), rhesus monkeys were given iv boluses of DCF. Simultaneous blood and cerebrospinal fluid (CSF) samples were assayed for DCF levels at times ranging from 10 minutes to 6 hours after the drug was given. Average peak CSF drug levels of 5.5 X 10(-8) M and 3 X 10(-7) M were reached 1 1/2 - 2 hours following injections of 0.25 and 1.0 mg DCF/kg, respectively. The ratio of peak CSF to simultaneous plasma levels was 1 to 10. Data obtained from a patient who had acute lymphocytic leukemia and who was given iv DCF were comparable. Drug levels achieved within the CSF following iv administration of 0.25 mg DCF/kg are similar to those previously demonstrated to inhibit ADA. These results may be important both for understanding DCF-related CNS toxicity and for designing combination chemotherapy with DCF.
Assuntos
Coformicina/líquido cefalorraquidiano , Leucemia Linfoide/líquido cefalorraquidiano , Ribonucleosídeos/líquido cefalorraquidiano , Animais , Barreira Hematoencefálica , Criança , Coformicina/administração & dosagem , Coformicina/análogos & derivados , Coformicina/sangue , Meia-Vida , Humanos , Injeções Intravenosas , Cinética , Macaca mulatta , Masculino , PentostatinaRESUMO
2'-Deoxycoformycin (dCF), a potent inhibitor of adenosine deaminase, has recently undergone Phase I clinical trials and has been found to be therapeutically active in acute lymphoblastic leukemia. In this report, levels of dCF in plasma, plasma concentrations of adenosine and deoxyadenosine, and urine levels of deoxyadenosine were measured in leukemic patients undergoing treatment with dCF during a Phase I clinical trial. dCF was administered i.v. at a dose of 0.25 to 1.0 mg/kg (7.5 to 30 mg/sq m) for 3 consecutive days. Plasma drug levels of 2 to 6 microM were observed following the third dose of dCF, and drug accumulation occurred only at the 1-mg/kg dosage. In this limited series of patients, the plasma concentrations of adenosine and deoxyadenosine and the urine concentrations of deoxyadenosine did not show an obvious correlation with dCF dose, therapeutic response, or toxicity.
Assuntos
Adenosina/sangue , Coformicina/sangue , Desoxiadenosinas/sangue , Leucemia Linfoide/sangue , Ribonucleosídeos/sangue , Adolescente , Adulto , Criança , Pré-Escolar , Coformicina/análogos & derivados , Coformicina/uso terapêutico , Coformicina/urina , Desoxiadenosinas/urina , Avaliação de Medicamentos , Feminino , Humanos , Leucemia Linfoide/tratamento farmacológico , Masculino , Pentostatina , Fatores de TempoRESUMO
The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes. Contrary to prior reports from this laboratory, the inactivation of intraerythrocytic ADA by dCF was linear rather than log-linear, with time. Linear inactivation rates were also seen when erythrocytes were preloaded with a 5-fold excess of calf intestinal ADA. The uptake of tritium-labeled dCF molecules and the rate of inactivation of ADA molecules showed an approximate 1:1 stoichiometry. The nucleoside transport inhibitors, 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine (NBMPR) and dipyridamole, and the permeant, uridine, inhibited dCF transport with Ki values of 35 nM, 45 nM, and 340 microM respectively. The affinity of dCF for the nucleoside transporter was low with a Ki of approximately 10 mM for the inhibition of adenosine influx.
Assuntos
Inibidores de Adenosina Desaminase , Coformicina/sangue , Eritrócitos/metabolismo , Nucleosídeo Desaminases/antagonistas & inibidores , Ribonucleosídeos/sangue , Transporte Biológico , Coformicina/análogos & derivados , Dipiridamol/farmacologia , Humanos , Cinética , Nucleosídeos/metabolismo , Pentostatina , Tioinosina/análogos & derivados , Tioinosina/farmacologia , Trítio , Uridina/farmacologiaRESUMO
Isocoformycin is a structural isomer of coformycin which has been demonstrated to be a potent inhibitor of adenosine deaminase. Isocoformycin showed a weaker inhibition of this enzyme than coformycin; the binding of coformycin to enzyme was irreversible, but isocoformycin inhibition was competitive with substrate. The Ki value of isocoformycin was 4.5 approximately 10 X 10(-8) M. Following intraperitoneal injection of isocoformycin in mice, the adenosine deaminase activity of homogenates of several organs was determined and the following ED50 values (50% inhibition doses) were observed: 29 mg/kg for thymus, 13 mg/kg for spleen, 80 mg/kg for liver and 20 mg/kg for kidney. The inhibition of adenosine deaminase in rabbit blood in vitro was also tested in comparison with coformycin.